SYNBIOTIC SE (SBX.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:SBX - DE000A3E5A59 - Common Stock
2.455 EUR
-0.01 (-0.41%)
We assign a fundamental rating of 0 out of 10 to SBX. SBX was compared to 55 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of SBX have multiple concerns. SBX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
1.2 Ratios
- The profitability ratios for SBX are negative, so there is not much use analyzing them.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for SBX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- SBX does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for SBX has been increased compared to 1 year ago.
- The debt/assets ratio for SBX is higher compared to a year ago.
2.2 Solvency
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | N/A |
ROIC/WACCN/A
WACC7.4%
2.3 Liquidity
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | N/A | ||
| Quick Ratio | N/A |
3. Growth
3.1 Past
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
- SBX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
SYNBIOTIC SE / SBX.DE FAQ
Can you provide the ChartMill fundamental rating for SYNBIOTIC SE?
ChartMill assigns a fundamental rating of 0 / 10 to SBX.DE.
What is the valuation status of SYNBIOTIC SE (SBX.DE) stock?
ChartMill assigns a valuation rating of 0 / 10 to SYNBIOTIC SE (SBX.DE). This can be considered as Overvalued.
How profitable is SYNBIOTIC SE (SBX.DE) stock?
SYNBIOTIC SE (SBX.DE) has a profitability rating of 0 / 10.